KLOW Stack
The KLOW stack is an advanced four-peptide blend adding KPV (anti-inflammatory alpha-MSH tripeptide) to the GLOW stack (GHK-Cu, BPC-157, TB-500). KPV provides systemic immune modulation and NF-κB inhibition, amplifying the repair efficacy of the other three peptides.
🔬 Mechanism of Action
The KLOW stack extends the GLOW stack by adding KPV — a fourth peptide that provides a systemic anti-inflammatory layer, unlocking a wider range of therapeutic applications.
**GLOW component mechanisms** (see GLOW stack entry for full detail) - GHK-Cu: Collagen/elastin upregulation, antioxidant enzyme stimulation, hair follicle cycling - BPC-157: VEGF/FGF-driven angiogenesis, fibroblast migration, nitric oxide modulation - TB-500: Actin sequestration, systemic cell migration, stem cell recruitment
**KPV (Lysine-Proline-Valine) — The differentiator** KPV is the C-terminal tripeptide of alpha-MSH (α-Melanocyte Stimulating Hormone) — specifically the active fragment that provides its anti-inflammatory effects without melanocortin receptor-mediated side effects (no skin darkening, no sexual arousal).
KPV inhibits NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) — the master transcription factor that controls production of pro-inflammatory cytokines: TNF-α, IL-1β, IL-6, and IL-8. By suppressing this pathway, KPV: 1. Reduces the inflammatory environment that impairs BPC-157 and TB-500 tissue repair activity 2. Shows efficacy in gut inflammation (Crohn's, IBD models) via oral and systemic routes 3. Reduces skin inflammation and has shown efficacy in dermatitis models 4. Is uniquely effective in an oral route — unlike most peptides, KPV can survive gastric passage sufficiently to produce GI anti-inflammatory effects
**Why KLOW > GLOW for inflammatory conditions**: In chronic inflammation, the NF-κB pathway continuously generates cytokines that damage tissue faster than repair peptides can heal it. KPV's NF-κB inhibition removes this "anti-healing" pressure, allowing BPC-157 and TB-500 to work significantly more effectively.
Source: PMID: 10817504 (KPV), PMID: 18492131 (GHK-Cu), PMID: 29936067 (BPC-157), PMID: 20435714 (TB-500)
💉 Dosing Protocol
| Typical Dose | BPC-157 250 mcg/day · TB-500 2.5 mg 2×/wk · GHK-Cu 1–2 mg/day · KPV 200–500 mcg/day |
| Frequency | Daily (GHK-Cu, BPC-157, KPV) · 2× weekly (TB-500) |
| Half-Life | Mixed (0.5–4 hours per component) |
| Common Vial Sizes | 5 mg, 10 mg, 50 mg |
🧪 Reconstitution Example
⚠️Safety & Considerations
All KLOW components are research peptides not FDA-approved for human use. KPV has been studied in Crohn's disease and IBD models with a favorable safety profile. Due to the angiogenic properties of BPC-157 and TB-500, KLOW should not be used by individuals with active malignancies. KPV is available as injectable or oral peptide — oral is particularly interesting for gut applications. Use sterile technique for all injections.
